Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02101476 · ClinicalTrials.gov registry record · Phase 4

An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.

A Phase 4 study of Post Operative Pain, sponsored by Lotus Clinical Research.

Completed
Registry status
Phase 4
Development phase
114
Enrollment target
1
Study location

NCT02101476 is a Phase 4 study of Post Operative Pain that has completed, run by Lotus Clinical Research. The registered enrollment target is 114 participants, below the 234-participant average among 56 other Post Operative Pain trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02101476, a Phase 4 study of Post Operative Pain, has completed, sponsored by Lotus Clinical Research.

COMPLETED
Registry status
Phase 4
Development phase
114 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the analgesic efficacy of Xartemis 15mg/650mg by mouth every 12 hours for the management of acute moderate to severe post operative pain to generic Oxycodone/APAP(acetaminophen) (Percocet) 10mg/650mg by mouth every 6 hours.

Conditions Studied

Interventions

  • DRUG Percocet
  • DRUG Xartemis

Study Locations (1)

California

  • Lotus Clinical Resarch,LLC - Pasadena

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2014-05
Est. Completion 2014-10
Phase Phase 4

Sponsor

Lotus Clinical Research

5 total trials

What the Registry Record Tells You About NCT02101476

The ClinicalTrials.gov registry entry for NCT02101476 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 234-participant average among 56 other Post Operative Pain trials with a reported enrollment target (51% lower). The listed sponsor is Lotus Clinical Research, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post Operative Pain appearing as the primary indexed condition, and to 2 interventions - of which Percocet is the first listed.

NCT02101476 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02101476 about?

NCT02101476 is a clinical study titled "An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.". The purpose of this study is to compare the analgesic efficacy of Xartemis 15mg/650mg by mouth every 12 hours for the management of acute moderate to severe post operative pain to generic Oxycodone/APAP(acetaminophen) (Percocet) 10mg/650mg by mouth every 6 hours.

What is the current status of trial NCT02101476?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2014-05. Estimated completion is 2014-10.

What conditions does trial NCT02101476 study?

This clinical trial studies the following conditions: Post Operative Pain.

What interventions are being tested in trial NCT02101476?

The interventions under investigation include: Percocet (DRUG), Xartemis (DRUG).

Who is sponsoring clinical trial NCT02101476?

This trial is sponsored by Lotus Clinical Research, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02101476 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post Operative Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.